BLSM BlossomHill Therapeutics, Inc.
Fundamentals / CIK 0001839970 / USDBlossomHill Therapeutics, Inc. reported $124.1M in total assets through June 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open BLSM in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Jun 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Jun 30, 2026$95.38M Total debt: $1.15M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research & Development | $21.93M | $21.36M | $14.67M | $12.53M |
| Total Operating Expenses | $25.48M | $24.67M | $16.73M | $14.10M |
| Operating Income | -$25.48M | -$24.67M | -$16.73M | -$14.10M |
| Net Income | -$24.01M | -$23.76M | -$15.98M | -$13.24M |
| Basic EPS | -$1.29 | -$8.75 | -$6.54 | -$5.51 |
| Diluted EPS | -$1.29 | -$8.75 | -$6.54 | -$5.51 |
| Basic Shares Outstanding | 18.6M | 2.7M | 2.4M | 2.4M |
| Diluted Shares Outstanding | 18.6M | 2.7M | 2.4M | 2.4M |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-06-30 | 2025-12-31 |
|---|---|---|
| Cash & Cash Equivalents | $95.38M | $136.7M |
| Cash & Short-Term Investments | $95.38M | $136.7M |
| Total Current Assets | $101.0M | $138.8M |
| Property, Plant & Equipment, Net | $1.49M | $1.73M |
| Other Non-Current Assets | $2.48M | $2.50M |
| Total Non-Current Assets | $23.16M | $24.14M |
| Total Assets | $124.1M | $163.0M |
| Accounts Payable | $3.93M | $2.31M |
| Other Current Liabilities | $809K | $0 |
| Total Current Liabilities | $18.62M | $15.48M |
| Other Non-Current Liabilities | $1.25M | $0 |
| Total Non-Current Liabilities | $23.47M | $22.39M |
| Total Liabilities | $42.09M | $37.87M |
| Total Debt (incl. Leases) | $1.15M | $5.0K |
| Common Stock | $1.0K | $1.0K |
| Retained Earnings | -$179.8M | -$135.0M |
| Total Stockholders' Equity | -$174.8M | -$131.7M |
| Total Equity | -$174.8M | -$131.7M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net Income | -$24.01M | -$23.76M | -$15.98M | -$13.24M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Current Ratio | -- | 5.42x | -- | -- |
| Quick Ratio | -- | 5.12x | -- | -- |